Title: Nordic Nanovector – Status of bookbuilding
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL
Nordic Nanovector AS ("Nordic Nanovector" or the "Company") updates the market on the status of the bookbuilding for the Company's private placement of up to NOK 150 million. Reference is made to the press release from the Company dated 6 June 2014.
The joint managers in the private placement have now registered orders within the indicative price range which more than cover the private placement for up to NOK 150 million. The bookbuilding period runs until 16:30 CET on 17 June 2014.
ABG Sundal Collier and DNB Markets are acting as managers in connection with the private placement.
The net proceeds from the private placement will be used to finance the further development of Betalutin™ for treatment of non-Hodgkin Lymphoma.
Jan A. Alfheim, CEO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 46 44 00 45
Fax: ( 47) 22 58 00 07
E-mail: jaa@nordicnanovector.no
Tone Kvåle, CFO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 91 51 95 76
Fax: ( 47) 22 58 00 07
E-mail: tkv@nordicnanovector.no
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat Non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
Tags:
